E2208 – Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb  Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer

 

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.

  • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study intended for promotional use among health care professionals.

Additional Information at ClinicalTrials.gov:

NCT01142388